A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

NCT05880927 ·Status: RECRUITING ·Phase: PHASE2

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

NCT03919253 ·Status: UNKNOWN ·Phase: PHASE2

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

NCT01937689 ·Status: COMPLETED ·Phase: PHASE1

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

NCT05429294 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients

NCT05839288 ·Status: COMPLETED

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT03412383 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

NCT04152057 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Pyrotinib in HER2-positive Early Breast Cancer

NCT06718335 ·Status: NOT_YET_RECRUITING ·Phase: NA

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

NCT04407988 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

NCT06035016 ·Status: RECRUITING

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT05561686 ·Status: UNKNOWN

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

NCT04659499 ·Status: UNKNOWN ·Phase: PHASE2

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

NCT06770296 ·Status: RECRUITING ·Phase: PHASE1

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

NCT04033172 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

NCT06144944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

NCT03993964 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

NCT04900311 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab

NCT04255056 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

NCT05572645 ·Status: COMPLETED

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT03980054 ·Status: UNKNOWN ·Phase: PHASE3

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

NCT05020964 ·Status: UNKNOWN ·Phase: PHASE2

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

NCT05910398 ·Status: RECRUITING ·Phase: PHASE3

Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy

NCT07189884 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

NCT06537674 ·Status: NOT_YET_RECRUITING

Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

NCT07014410 ·Status: RECRUITING ·Phase: PHASE2